Daniel Chevallard Net Worth & Insider Trades
Daniel Chevallard - Chief Financial Officer, Regulus Therapeutics Inc
What is Daniel Chevallard's Net Worth?
The current estimated net worth of Regulus Therapeutics Inc's Chief Financial Officer, Daniel Chevallard, is estimated to be about $364.65K . Daniel Chevallard owns about 77,870 units of Regulus Therapeutics Inc common stock. In the last 2 years at Regulus Therapeutics Inc, Daniel Chevallard has sold an estimated value of $20.78K worth.
What is Daniel Chevallard's Past Insider Trading?
Daniel Chevallard's largest purchase order was 54,945 units , worth over $50K on July 25, 2017. Daniel Chevallard's largest sale order was 10,000 units , worth over $14.09K on May 16, 2019. In total, Daniel Chevallard has made about 8 transactions over 2 years of their time at Regulus Therapeutics Inc. Daniel Chevallard usually trades in May, with the busiest year in 2019. The most recent transaction was a sale order of 2,669 units , worth over $3.5K on July 2, 2019.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Daniel Chevallard
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |
InsideArbitrage
What is Daniel Chevallard's' Mailing Address?
- Mailing address is C/o Regulus Therapeutics Inc. 10614 Science Center Drive San Diego CA 92121 CA
What are Regulus Therapeutics Inc's Past Insider Trades?
Regulus Therapeutics Inc's most recent insider trade came on March 1, 2022 by Denis Drygin who bought 76,686 units worth $17.64K . In the last 10 years, insiders at Regulus Therapeutics Inc have sold an estimated value of $79.77M and bought an estimated value of $68.89M worth of shares. Insider trading is most common in June, with the busiest year in 2019. The most active traders at the company are Joseph Hagan, President and CEO, Stelios Papadopoulos, Director, and Christopher Aker, Sr. VP & General Counsel .
Regulus Therapeutics Inc. Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
---|---|---|---|---|---|---|---|
No matching records found |